Certara

Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017, and is headquartered in Princeton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Certara surpasses revenue expectations, eyes global expansion and innovation

Certara's strong financial performance in Q4 2022 and exceeding revenue guidance for the full year underscore the company's growth trajectory and market positioning.
With a focus on software, biosimulation services, and global expansion, Certara is poised for continued success in 2023 and beyond.
The company's proactive engagement with regulatory bodies, strategic acquisitions, and partnerships signal a commitment to innovation and sustainable growth.

Certara reports robust Q1 earnings driven by biosimulation strength

Certara's Q1 2023 showcased solid financial performance, particularly in software and biosimulation services. Despite challenges in deal closure times and subscription model impact, the company remains optimistic about future growth opportunities.

Certara reports solid Q2 earnings, eyes growth through AI integration

Certara's Q2 performance showed growth in both software and services revenue, with adjusted EBITDA at $32.4 million.
The company faces challenges from cautious spending and slow recovery in regulatory business but remains optimistic about long-term industry potential.
Strengths include acquisitions enhancing AI capabilities, focus on accelerating projects, and expanding key offerings.
Opportunities lie in integrating AI, driving growth in biosimulation services, and aiming for higher growth in 2024.

Certara reports stable Q3 performance, eyes growth in biosimulation and AI

Certara's Q3 performance showed revenue growth driven by software, despite challenges in services revenue.
The company remains confident in its strategies and outlook for growth, focusing on biosimulation and AI integration.
While facing uncertainties in closing AI product deals, Certara sees opportunities in market demand and long-term growth.
Analysts' inquiries during the call highlighted areas of concern but also underscored Certara's strengths and potential for expansion.

Certara reports steady revenue growth, eyes software investments for 2024

Certara's Q4 2023 performance reflects a mixed revenue picture with software revenue growth offsetting a decline in services revenue, while the company maintains a strong financial position.
Strategic acquisitions, growth initiatives in key markets, and a focus on operational efficiency present avenues for Certara to drive future growth and enhance market competitiveness.
Challenges lie in balancing revenue streams, managing margin pressures from investments, and navigating market uncertainties, requiring strategic decision-making and operational agility.
Overall, Certara's outlook for 2024 is optimistic, underpinned by confidence in growth drivers, strategic acquisitions, and a commitment to innovation and market expansion.

Certara reports solid Q1 performance and eyes revenue acceleration

Certara's Q1 performance reflects growth in software revenue and steady services revenue, with a focus on operational efficiency and strategic goals for 2024.
Challenges include seasonality in services bookings and the need for further restructuring, while opportunities lie in potential revenue acceleration and market dynamics.
Overall, Certara remains optimistic for the year ahead, maintaining revenue and EPS guidance for 2024 and aiming for margin improvement in the second half.

Certara reports Q2 revenue growth, acquires Chemaxon for innovation

Certara's Q2 performance showed mixed results with revenue growth driven by Software but offset by a decline in Services, while bookings and adjusted EBITDA demonstrated positive momentum.
The company's strategic strengths lie in recent acquisitions, product innovations, and a focus on software and AI investments to drive future growth and profitability.
Challenges include addressing declines in the Services segment, improving performance with Tier 1 customers, and managing operational costs to reduce net losses.
Opportunities for Certara include meeting full-year revenue guidance, leveraging software and AI investments for industry leadership, and expanding market presence through recent acquisitions and product releases.

Certara reports strong Q3 earnings, focuses on biosimulation growth

Certara's Q3 performance was strong, driven by revenue growth and strategic investments in software and commercial reach.
While facing challenges in the regulatory services market, Certara is focused on leveraging opportunities from the Chemaxon acquisition and uniting R&D and sales efforts for sustainable growth.
The company's financial position is robust with healthy cash reserves, but managing debt levels and maintaining margins in regulatory services remain key challenges.
Certara's outlook for 2024 is positive, with updated guidance indicating revenue of $380-385 million and adjusted EBITDA of $120-124 million.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017, and is headquartered in Radnor, PA.

Certara Inc's (CERT) CEO William Feehery on Q2 2021 Results - Earnings Call Transcript

Certara Inc (NASDAQ: CERT) has agreed to acquire Pinnacle 21 for $310 million in cash and stock.  Pinnacle 21's software tools are used to validate compliance to the Clinical Data Interchange Standards Consortium (CDISC) standards, which the FDA requires, Japan's Pharmaceuticals and Medical Devices Agency, and preferred by China's National Medical Products Administration.

Certara To Buy Compliance Software Provider For $310; Q2 Earnings Beat Expectations, Raises FY21 Guidance

Raises full year 2021 guidance and announces deal to acquire Pinnacle 21 Raises full year 2021 guidance and announces deal to acquire Pinnacle 21

Certara Reports Second Quarter 2021 Financial Results

Transaction expected to be accretive to Certara's revenue, revenue growth and adjusted EBITDA margin Transaction expected to be accretive to Certara's revenue, revenue growth and adjusted EBITDA margin

Certara to Acquire Pinnacle 21, a Leader in Data Standardization Software for Pharmaceutical Clinical Data

PRINCETON, N.J., July 27, 2021 (GLOBE NEWSWIRE) -- Certara (NASDAQ: CERT), a global leader in biosimulation, today announced that Mubadala Investment Company (Mubadala) has made an approximately $250 million investment in Certara. The investment aligns with Mubadala's strategy of enabling innovation to address unmet clinical needs and drive cost efficiencies.

Mubadala Invests in Global Biosimulation Leader Certara

Clinical Study Confirms Quantitative Systems Pharmacology (QSP) Prediction, Showcasing the Power of Biosimulation Technology Clinical Study Confirms Quantitative Systems Pharmacology (QSP) Prediction, Showcasing the Power of Biosimulation Technology

Certara's Vaccine Simulator™ Accurately Predicted Optimal Timing Between Doses for COVID-19

PRINCETON, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- Certara, a global leader in biosimulation, today announced the appointments of Nancy Killefer and Cynthia Collins to its board of directors, effective August 1, 2021. The two additional appointments increase the company's board of directors to eleven members.

Certara Appoints Nancy Killefer and Cynthia Collins as New Independent Board Members

PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2021 after the market close on Thursday, August 5, 2021. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Certara to Report Second Quarter 2021 Financial Results on August 5, 2021

Veteran HR leader brings 20+ years of human resources experience to the company's executive team Veteran HR leader brings 20+ years of human resources experience to the company's executive team

Certara Announces New Chief Human Resources Officer

Major Release to Help Life Science Companies Maximize Go-to-Market Impact Major Release to Help Life Science Companies Maximize Go-to-Market Impact

Certara Announces Update of BaseCase Software, the Company's Value Communication Platform

The PMDA enters 8th consecutive year of using Certara's biosimulation software The PMDA enters 8th consecutive year of using Certara's biosimulation software

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara's Biosimulation Software for Evaluating Regulatory Submissions

Dr. Gallagher brings more than 30 years of drug development and commercial leadership experience to her new role Dr. Gallagher brings more than 30 years of drug development and commercial leadership experience to her new role

Certara Appoints Dr. Carol Gallagher as New Independent Board Member

PRINCETON, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that William Feehery, Chief Executive Officer, and Andrew Schemick, Chief Financial Officer, will participate in the following virtual investor conferences:

Certara to Participate in the William Blair Growth Stock Conference and Jefferies Virtual Healthcare Conference

Expanded capabilities in company's Immunogenicity and Immuno-oncology QSP Simulators broaden applicability for addressing safety and efficacy challenges Expanded capabilities in company's Immunogenicity and Immuno-oncology QSP Simulators broaden applicability for addressing safety and efficacy challenges

Certara Releases New Versions of Its Preeminent Quantitative Systems Pharmacology (QSP) Simulators for Expediting Development of Biologics and Immuno-oncology Therapies

Certara, Inc. (CERT) CEO William Feehery on Q1 2021 Results - Earnings Call Transcript

PRINCETON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2021.

Certara Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Guidance

First-of-its-kind software predicts likelihood of off-target safety issues that could impede clinical progress First-of-its-kind software predicts likelihood of off-target safety issues that could impede clinical progress

Certara Launches Secondary Intelligence™ Software to Predict Risk of Unwanted Side Effects of Drug Candidates Earlier

PRINCETON, N.J.--(BUSINESS WIRE)--Certara's CEO, William Feehery, and CFO, Andrew Schemick, are scheduled to present in the BofA Securities 2021 Virtual Health Care Conference.

Certara to Present at the BofA Securities 2021 Virtual Health Care Conference

Certara is a midsized developer of software for biosimulation. The company has impressive revenues and a strong business model.

Certara: Using Computer Modelling To Aid Biopharma R&D

PRINCETON, N.J.--(BUSINESS WIRE)--Certara today announced that it will release preliminary financial results for the first quarter of 2021 after market close on May 6, 2021.

Certara to Report Preliminary First Quarter 2021 Financial Results on May 6, 2021

PRINCETON, N.J.--(BUSINESS WIRE)-- #anonymization--TrialAssure® – a leading, global software company advancing clinical trial disclosure, data sharing, and transparency – has announced today that Certara (Nasdaq: CERT) – the global leader in biosimulation – has licensed TrialAssure's ANONYMIZE software to anonymize clinical data. TrialAssure's ANONYMIZE for Data provides a cutting-edge anonymization application for datasets that allows clinical trial sponsors to anonymize all structured clinical trial data, inc

Certara Adopts TrialAssure ANONYMIZE Solution to Speed Life Science Industry Need to Meet Regulatory Requirements for Data Sharing

PRINCETON, N.J.--(BUSINESS WIRE)--Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it is set to join the Russell 1000® Index.

Certara Set to Join Russell 1000® Index

Certara, Inc. (CERT) CEO William Feehery on Q4 2020 Results - Earnings Call Transcript

PRINCETON, N.J.--(BUSINESS WIRE)--Certara, a global leader in biosimulation, today reported its preliminary results for the fourth quarter and full year ending December 31, 2020.

Certara Reports Preliminary Fourth Quarter and Full Year 2020 Results and Issues Full Year 2021 Guidance

PRINCETON, N.J.--(BUSINESS WIRE)--Certara today announced that William Feehery, CEO and Andrew Schemick, CFO will virtually present at the Barclays Global Healthcare Conference.

News for Certara Stock (CERT)